okay, so let's look at the #ACR21 plenary as we go so a reminder - FDA-mandated phase 3b/4 safety endpoint study specifically looking at patients >50yo with at least one other CV risk factor today we're looking at MACE: that's CV death (excl PE), MI, stroke ABST0958 @RheumNow https://t.co/9U8Sahb9Q7

Abst#0946 shows a distinct lipid profile in RA vs PsA synovium + synovial fluid. Sphingomyelins & phosphatidyl-cholines/ethanolamines had the greatest separation power to classify RA + PsA samples. These lipid markers may have clinical utility if validated. #ACR21 @Rheumnow https://t.co/ktKRypTtlE

Outcomes of COVID-19 in Patients with Rheumatoid Arthritis. Dr. Akhil Sood ( @AkhilSoodMD) shares the studies presented #ACR21. https://t.co/yrs8N8XSiS https://t.co/EKHuTS5aDr

• https://bit.ly/2YmsXym

VITAL RCT of Omega-3 and Vit D in preventing autoimmune diseases in 25,871 individuals. They both work! Reducing incident autoimmune disease by 25-30%. This is game-changing! Abstr#0957 #ACR21 @RheumNow #ACRBest https://t.co/BaeZDTTnQf

#ACR21 Abst#0836. TCZ switch from IV▶️SC in RA ⭐️11/37 ineffective on SC (30%) ⭐️TCZ IV >8mg/kg, no MTX, h/o ABA failure ass w/ risk of flare on SQ switch 🔥Very relevant w shortages, want more data re: confounders (adherence, disease control) https://t.co/E9pD4SrXqz @Rheumnow

• https://bit.ly/3keDrHK

#ACR21 Abs#0834: CorEvitas Registry TNFi vs IL-6 in RA ⭐️IL6 pts older, longer h/o RA, higher CDAI, more prior Rx ▶️ No difference in outcomes bw IL6 and TNFi (monotherapy or combo w MTX). ▶️1/3 of pts achieved LDA Limits: real-world, unblinded https://t.co/AJtzeMuj1T @Rheumnow

• https://bit.ly/3qdAU4s

Dr Jin @SeoyoungCKim population-based study on predictors of switching after 1st line TNFi use. 22% switch, most to 2nd TNFi.👩, prior steroid use predicted change, other autoimmune disease and vit D use negative predictors. Abstr#579 #ACR21 @RheumNow https://t.co/YpZ5rGBiod

Jorge Plutzky, cardiologist perspective on RA at #ACR21 ⭐️CANTOS: Canakinumab for MACE shows ⬇️ inflammation, no change in LDL. Improvement in MACE events ▶️Plutzky: "Proof of concept study" @Rheumnow https://t.co/Xi9ZHxMtmu

Another benefit of DMARD use in RA. Dr Sood reports lower risk of long term opioid use. Very important given the harm of opioids Abstr#587 #ACR21 @RheumNow https://t.co/d1Dharf5jZ

We need to control not only inflammation but also lipids levels in our patients w/ IA! Dr Plutzky brilliantly talking us through CV risk and RA showing data on how poor LDL control and coronary microvascular dysfunction lead to worse long term CV outcomes. @RheumNow #ACR21 https://t.co/o6GWHDai5z